Idoxifene
Clinical data
Other namesCB-7432, SB-223030; Pyrrolidino-4-iodotamoxifen; 4-Iodopyrrolidinotamoxifen
Routes of
administration		Oral
Pharmacokinetic data
Elimination half-lifeAcute: 15 hours[1]
Chronic: 23 days[1]
Identifiers
  • 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H30INO
Molar mass523.458 g·mol−1
3D model (JSmol)
  • CC/C(=C(/C1=CC=C(C=C1)OCCN2CCCC2)\C3=CC=C(C=C3)I)/C4=CC=CC=C4
  • InChI=1S/C28H30INO/c1-2-27(22-8-4-3-5-9-22)28(23-10-14-25(29)15-11-23)24-12-16-26(17-13-24)31-21-20-30-18-6-7-19-30/h3-5,8-17H,2,6-7,18-21H2,1H3/b28-27-
  • Key:JJKOTMDDZAJTGQ-DQSJHHFOSA-N

Idoxifene (INN, USAN, BAN) (former developmental code names CB-7432, SB-223030), also known as pyrrolidino-4-iodotamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group which was under development for the treatment of breast cancer and postmenopausal osteoporosis but was never marketed.[1][2][3] It reached phase III clinical trials for postmenopausal osteoporosis and phase II clinical trials for breast cancer before development was discontinued in 1999 due to insufficient effectiveness in both cases.[1]

Chemistry

Synthesis

A large-scale chemical synthesis of idoxifene has been devised.[4]

References

  1. 1 2 3 4 "Idoxifene". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Miller WR, Ingle JN (8 March 2002). Endocrine Therapy in Breast Cancer. CRC Press. pp. 58–. ISBN 978-0-203-90983-6.
  3. ↑ McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB (December 1989). "Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent". Journal of Medicinal Chemistry. 32 (12): 2527–2533. doi:10.1021/jm00132a006. PMID 2585441.
  4. ↑ McCague R, Potter GA, Jarman M (1994). "An Efficient, Large‐Scale Synthesis of Idoxifene ((E)‐1‐(4‐(2‐(N‐Pyrrolidino) ethoxy) phenyl)‐1‐(4‐Iodophenyl)‐2‐phenyl‐1‐butene)". Organic Preparations and Procedures International. 26 (3): 343–346. doi:10.1080/00304949409458432. ISSN 0030-4948.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.